Glenmark Pharmaceuticals Limited · NSE:GLENMARK

Glenmark Pharmaceuticals — Q3 FY26 Earnings Presentation

15 slides from Glenmark Pharmaceuticals's earnings presentation, Jan 30, 2026

  1. Slide 1: Exchange filing cover letter: Investor Presentation

    January 30, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 532296

  2. Slide 2: Investor Presentation: Q3 FY26

    Investor Presentation: Q3 FY26 30 January 2026

  3. Slide 3: Disclaimer

    Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statemen

  4. Slide 4: Q3 FY26 Summary

    Q3 FY26 Summary Consolidated • Consolidated Revenue of Rs. 39,006 Mn “We delivered strong double-digit revenue growth in the third quarter, Revenue • YoY growth of 15.1% reflecting disciplined execution across markets and keeping us on track to deliver our near-term guidance. India continued to outp

  5. Slide 5: Consolidated Revenue – Q3 and 9M FY26

    Consolidated Revenue – Q3 and 9M FY26 Third Quarter ended December 31 Nine Months ended December 31 YoY Growth YoY Growth Rs. Million FY 2025-26 FY 2024-25 FY 2025-26 FY 2024-25 (%) (%) India 12,986 10,637 22.1% 27,036 35,415 -23.7% North America 9,706 7,813 24.2% 62,142 23,026 169.9% Europe 7,963 7

  6. Slide 6: India

    India Revenue (Rs. million) Ranked 2nd in Dermatology, Launched world’s first YoY: 22.1% 2nd in Respiratory and 4th nebulized fixed-dose triple 12,986 in the Cardiac segment# therapy for COPD 10,637 Key Highlights  Continued outperformance as per IQVIA - Secondary sales growth of 15.8% and 13%, com

  7. Slide 7: North America

    North America Revenue (Rs. million) YoY: 24.2% 4 new injectable products EIR received for Monroe launched with a VAI 9,706 # 7,813 Key Highlights  Net of the out-licensing income for ISB 2001, the core business YoY growth was 4.1% in Q3 FY26  Launched 4 products: 8.4% Sodium Bicarbonate Injection

  8. Slide 8: Europe

    Europe Revenue (Rs. million) YoY: 9.1% Strong performance from WINLEVI® approved in EU, overall Respiratory portfolio to be launched in Q1 FY27 7,963 7,297 Key Highlights  Strong recovery due to the onset of the winter season which aided growth of the Q3 FY26 Q3 FY25 Respiratory portfolio  Continu

  9. Slide 9: Emerging Markets (EM)

    Emerging Markets (EM)1 Revenue (Rs. million) YoY: 8.4% Strong return to growth for RYALTRIS® continuing to APAC, LATAM markets scale up across markets 8,119 7,491 Key Highlights  Russia: Secondary sales growth of 15%; recorded faster secondary sales growth than Q3 FY26 Q3 FY25 the overall Dermatolo

  10. Slide 10: Global Innovative Portfolio

    Global Innovative Portfolio RYALTRIS®  As of December 2025, marketing applications submitted in more than 90 countries across the world; product commercialized in 52 markets.  Expected to be launched in 10-12 additional markets over the next few quarters  Continues to witness a strong uptake in m

  11. Slide 11: Global Innovative Portfolio

    Global Innovative Portfolio QiNHAYO™ (ENVAFOLIMAB)  Filed QiNHAYO Marketing Authorization Applications in 18 markets till date; the first commercial launch is expected in FY27.  Received authorization from the regulatory authority in Kenya, Mauritius and Uganda for supply of QiNHAYO™ via early acc

  12. Slide 12: Global Innovative Portfolio

    Global Innovative Portfolio AUMOLERTINIB PARTNERED WITH HANSOH PHARMA  Entered into an exclusive license, collaboration and distribution agreement with Hansoh Pharmaceutical Group Co. Ltd., for Aumolertinib, a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) fo

  13. Slide 13: Diversity Of Immune Cell Engagement And Indications Across Hematologic And Solid Tumours

    Diversity Of Immune Cell Engagement And Indications Across Hematologic And Solid Tumours INDICATIO DISCOVER PRE- GLOBAL ASSET DESCRIPTION PHASE 1 PHASE 2 PHASE 3 N Y CLINICAL RIGHTS CD38 x BCMA x CD3 Multiple ISB 2001 TREAT™ trispecific T- Cell Engager Myeloma Hidradenitis ISB 880 / ALM27134 IL-1RAP

  14. Slide 14: IGI - Key updates

    IGI - Key updates  ISB 2001/ABBV-2001 o IGI is currently executing a Phase 1 study (TRIgnite-1) in Australia, United States and several European countries. The study continued to Dose Expansion in April 2025 and is continuing to rapidly enrol patients.  ISB 2301: IMMUNITE™ Platform o First-in-clas

  15. Slide 15: Thank You

    G Glenmark Thank You

Glenmark Pharmaceuticals — Q3 FY26 Earnings Presentation on 6ix